Novartis Reports Results of Beovu (brolucizumab) in Two New Post-Hoc Analyses of P-III HAWK and HARRIER Studies for Wet AMD

October 6, 2020 Auto Bot Beovu, Clinical Trials, Novartis, P-III 0

Shots:

  • The P-III HAWK (6/3mg) & HARRIER (6mg) study assessing Beovu [q12w/q8w with the majority on q12w following the loading phase) vs aflibercept (2mg) in 1,800 patients with wet AMD across 400 centers
  • Results: first analysis ewer patients had early persistent fluid (12.5% vs 20.4%), defined as the presence of intra-retinal fluid or subretinal fluid through @12wks. treatment, patients gain greater BVCA (6.4 vs.3.7), CST control (80% vs 69%) respectively, presented at EURETINA
  •  Beovu is the first advanced humanized scFv, approved for clinical use in 40+ countries, including in the US, EU, UK, Japan, Canada, and Australia

Click here ­to­ read full press release/ article | Ref: Novartis | Image: Novartis

The post Novartis Reports Results of Beovu (brolucizumab) in Two New Post-Hoc Analyses of P-III HAWK and HARRIER Studies for Wet AMD first appeared on PharmaShots.